Following Kaitlyn’s recovery, Angharad said doctors cannot put her on the clinical trial because of a “relapse in her central ...

Pfizer’s Seagen portfolio grew 21%, while Padcev-Keytruda cut the risk of death by 35% in a bladder-cancer study. ・IBRX’s Anktiva revenue jumped 92% to $50.7 million as the company pursued a broader U ...

A clinical trial of rebecsinib, an experimental anti-cancer drug, is underway at UC San Diego for patients with two types of ...

LabPMM ®, an Invivoscribe ® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is ...

The Trump Organization and Eric Trump, the president's son, filed a lawsuit in March 2025 in a Florida federal court, alleging the accounts were closed because of Capital One's "woke" beliefs and its ...

OPTI-AML, a sub-study of Beat AML, compared the standard 28-day venetoclax schedule with a 14-day schedule, both given with ...

FIRST-time mum Rebecca Robinson was told her exhaustion and low iron levels were “common pregnancy symptoms”. She felt ...

A first-time mother was diagnosed with leukaemia 10 days after giving birth, having initially dismissed tiredness and bleeding gums as “common pregnancy symptoms”. At such a critical moment in US ...

A first-time mother whose tiredness and bleeding gums were thought to be “common pregnancy symptoms” has said she felt ...

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly ...

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...